key: cord-0797094-r9dvonzt
authors: Grunvald, Warren; Herrington, Ramsey; King, Roz; Lamberson, Miles; Mackey, Scott; Maruti, Sanchit; Rawson, Richard; Wolfson, Daniel
title: COVID‐19: A new barrier to treatment for opioid use disorder in the emergency department
date: 2021-03-17
journal: J Am Coll Emerg Physicians Open
DOI: 10.1002/emp2.12403
sha: 8a04f8e6d220cee4b8a012509aadabc3480096e2
doc_id: 797094
cord_uid: r9dvonzt

OBJECTIVE: Start Treatment and Recover (STAR) is an emergency department (ED) program that expands access to medication for opioid use disorder by identifying patients with opioid use disorder and offering ED‐initiated buprenorphine/naloxone and rapid access to outpatient treatment. We sought to determine the impacts of the coronavirus disease 2019 pandemic on STAR and the patients with opioid use disorder it serves. METHODS: We conducted a retrospective review of records comparing 2 periods: pre‐pandemic (February 1, 2019–February 29, 2020) and pandemic (March 1, 2020–May 31, 2020). Variables evaluated included the number of STAR enrollments, ED census, percentage of census screening positive for opioid use disorder, number and percentage of ED overdose visits, and overdose fatalities by month. All analyses were conducted using 2‐sample t tests to calculate the mean and 95% confidence intervals (CIs). RESULTS: Comparing the pre‐pandemic to the pandemic period, the mean monthly ED visits decreased from 5126.9 to 3306.7 (difference = −1820.3; 95% CI, −3406.3 to −234.2), STAR mean monthly enrollments decreased from 9.7 to 1.3 (difference = −8.4; 95% CI, −12.8 to −4.0), and statewide monthly opioid‐related fatalities increased from 9.4 to 15.3 (difference = 5.9; 95% CI, 0.8 to 11.1). However, the percentage of individuals who presented to the ED with opioid use disorder or overdose remained unchanged. CONCLUSION: Although overall ED visits declined during the pandemic period, the percentage of patients presenting with opioid use disorder or overdose remained constant, yet there was a dramatic decline in enrollment in ED‐initiated medication for opioid use disorder and an increase in statewide monthly opioid‐related fatalities. Strategies to maintain medication for opioid use disorder treatment options must be implemented for this vulnerable population during the ongoing pandemic.

Since coronavirus disease 2019 (COVID-19) was declared a pandemic, the United States, already in the midst of a devastating opioid epidemic, has seen an increase in fatal opioid-related overdoses. 1 Explanations for the connection between COVID-19 and the increased rates of opioid-related fatalities include social isolation, disruptions in medication for opioid use disorder, lack of access to mental health care services, increase in relapse, lack of access to harm reduction or health care services, increased homelessness and incarceration, and concurrent COVID-19 infection. 2 Emergency departments (EDs) are uniquely positioned to identify and initiate treatment for patients with opioid use disorder. Many EDs have implemented programs that initiate medication for opioid use disorder, consistently demonstrating that providing access to buprenorphine/naloxone leads to increased enrollment and maintenance in outpatient treatment programs. 3 

Opioid use disorder is a complex disease, and combatting opioid use disorder successfully requires a multisystem approach with significant time and resource allocation. The COVID-19 pandemic has disturbed this system and thus is having a negative impact on patients with opioid use disorder.

The purpose of this article is to describe the impact of COVID-19 on STAR and on patients with opioid use disorder who present to the ED.

A retrospective review of records was conducted comparing 2 periods:

pre-pandemic and pandemic. The pre-pandemic period was defined were administered an immediate 4 mg dose from the starter pack before discharge from the ED.

For each period, we assessed the ED census, percentage of patients screened positive for opioid use disorder, number of patients who presented with overdose, percentage of ED census with overdose, number of patients who screened positive for opioid use disorder, number of patients deemed eligible for STAR, and the number of patients enrolled in STAR by month. These data were obtained from UVMMC ED electronic medical records and the STAR program registry. For additional context, we also examined the statewide and local county opioid fatalities during each period. These data were obtained from the Vermont Department of Health vital records.

ED census, percentage of census screening positive for opioid use disorder, and number of ED overdose visits were used to assess for enrollment potential. STAR enrollments (primary outcome) were measured to gauge interest in engaging with medication for opioid use disorder. Chittenden County and statewide opioid-related fatalities were included to identify patterns of opioid use in the local community and larger statewide trends.

Variables were compared between the pre-pandemic and pandemic periods. All analyses were conducted using a 2-sample t tests using 

The monthly average number of ED visits decreased significantly from 5126.9 to 3306.7 between the pre-pandemic and pandemic periods Figure 2 ). Figure 2 ).

To account for potential seasonal variations in opioid use, the analysis was repeated using pre-pandemic data that were restricted to the Table 2 ). This is consistent with other research showing the total number of US ED visits was 42% lower than the same period a year earlier, 4 including fewer visits for acute processes such as stroke and acute coronary syndrome. 5 Moreover, patients with substance use disorders often experience stigma that prevents them from seeking care and engaging with medication for opioid use disorder. 6 Patients with opioid use disorder may decline emergency medical services (EMS) transport to the ED after an overdose because of concern around this stigma and/or fear of COVID-19 infection. Research has shown both an increase in EMS calls for opioid overdose and a significant increase in the number of patients who were treated on scene and refused transport during the pandemic. 7 A concerning pattern in the police record management system of Chittenden County found that 88% of overdose fatalities were attributed to using opioids in isolation. 8 Statewide opioid-related fatalities in Vermont increased by 63.4% during the pandemic period.

This suggests that COVID-19 has driven patients with opioid use disorder to riskier use, avoidance of treatment, and increased mortality.

Other factors may have contributed to the increased rate of overdose and overdose deaths as COVID-19 has also reduced access to medication for opioid use disorder in community outpatient settings. completing an enrollment and prolonging the process. Having to enroll over the phone rather than face to face may have also discouraged enrollment through the lack of a personal connection that an in-person interaction provides. Moreover, having to wait an extended duration in the ED after being medically cleared for discharge to complete the enrollment process may have further discouraged those who were already anxious about coming to the ED because of fears of COVID-19.

In summary, the COVID-19 pandemic is having a detrimental impact on patients with opioid use disorder presenting to the ED. Although overall ED visits decreased during the initial months of the pandemic, the percentage of patients presenting with opioid use disorder or overdose-related visits remained constant, yet there was a significant 86.2% decrease in the number of patients enrolling in ED-initiated medication for opioid use disorder. Allocation of healthcare resources and strategies devised to mitigate harm and maintain treatment options must be implemented for those struggling with opioid use disorder during the ongoing pandemic.

The authors declare no conflict of interest.

Daniel Wolfson and Warren Grunvald conceived the study. Daniel 

Issue Brief: Reports of Increases in Opioidrelated Overdose and Other Concerns during COVID Pandemic. Washington

The perfect storm: COVID-19, mass incarceration and the opioid epidemic

Emergency department-initiated buprenorphine for opioid dependence with continuation in primary care: outcomes during and after intervention

Impact of the COVID-19 pandemic on emergency department visits -United States

Potential indirect effects of the COVID-19 pandemic on use of emergency departments for acute lifethreatening conditions-United States

Stigma at every turn: health services experiences among people who inject drugs

Signal of increased opioid overdose during COVID-19 from emergency medical services data

Police Computer-aided Dispatch and Record Management System

Challenges posed by COVID-19 to people who inject drugs and lessons from other outbreaks

Collateral damage of COVID-19 pandemic: delayed medical care

BS, is a second-year medical student at University of Vermont Larner College of Medicine

COVID-19: a new barrier to treatment for opioid use disorder in the emergency department